TY - T1 - The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes SN - / UR - http://hdl.handle.net/10138/224129 T3 - A1 - Cherney, David; Lund, Soren S.; Perkins, Bruce A.; Groop, Per-Henrik; Cooper, Mark E.; Kaspers, Stefan; Pfarr, Egon; Woerle, Hans J.; von Eynatten, Maximilian A2 - PB - Y1 - 2016 LA - eng AB - Aims/hypothesis Sodium glucose cotransporter 2 (SGLT2) inhibition lowers HbA(1c), systolic BP (SBP) and weight in patients with type 2 diabetes and reduces renal hyperfiltration associated with type 1 diabetes, suggesting decreased intraglomerular hypertension. As lowering HbA(1c), SBP, weight and intraglomerular pressure is associated with antialbuminuric effects in diabetes, we hypothesised that SGLT2 inhibition would reduce the urine albumin-to-creatinine ratio (UACR) to a clinically meaningf... VO - IS - SP - OP - KW - Empagliflozin; Macroalbuminuria; Microalbuminuria; Sodium glucose cotransporter 2; Type 2 diabetes; Urine albumin-to-creatinine ratio; PLACEBO-CONTROLLED TRIAL; CHRONIC KIDNEY-DISEASE; DOUBLE-BLIND; SGLT2 INHIBITOR; LONG-TERM; ADD-ON; DIETARY-SODIUM; ALBUMINURIA; RATS; HYPERFILTRATION; 3121 General medicine, internal medicine and other clinical medicine N1 - PP - ER -